Flagship Pioneering’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
Other funds holding FHTX
BI
DM
EC
SL
Flagship Pioneering's FHTX Position: Q2 2026 in Review
Flagship Pioneering held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 12,674,120 shares worth $61.8M. The position accounts for 4.02% of the portfolio, ranked #4.
Flagship Pioneering first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $290M in Q4 2021. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.
- Flagship Pioneering held 12,674,120 shares of Foghorn Therapeutics worth $61.8M as of Q2 2026.
- Flagship Pioneering left its Foghorn Therapeutics share count unchanged in Q2 2026.
- Foghorn Therapeutics made up 4.02% of Flagship Pioneering's portfolio in Q2 2026, its #4 holding.
- Flagship Pioneering first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
- Flagship Pioneering's Foghorn Therapeutics position peaked at $290M in Q4 2021.
- 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.
Based on Flagship Pioneering's 13F filing for Q2 2026, filed 14 Aug 2026.